



Genomic Insights into Colistin-Resistant *Klebsiella pneumoniae* from a Tunisian Teaching Hospital

Nadia Jaidane,^{a,b,c,g} Rémy A. Bonnin,^{c,d,e} Wejdene Mansour,^{a,f} Delphine Girlich,^{c,d} Elodie Creton,^e Garance Cotellon,^e Cherifa Chaouch,^{a,b,g} Noureddine Boujaafar,^{a,b,g} Olfa Bouallegue,^{a,b,h} Thierry Naas^{c,d,e}

^aUR 12 SP 37, Emerging Bacterial Resistance and Safety of Care, Department of Clinical Microbiology, University Hospital of Sahloul, Sousse, Tunisia

^bClinical Microbiology Laboratory, University Hospital of Sahloul, Sousse, Tunisia

^cEA7361, Université Paris-Sud, Université Paris-Saclay, LabEx Lermite, Bacteriology-Hygiene Unit, APHP, Hôpital Bicêtre, Le Kremlin-Bicêtre, France

^dEERA Evolution and Ecology of Resistance to Antibiotics Unit, Institut Pasteur-APHP-Université Paris Sud, Paris, France

^eAssociated French National Reference Center for Antibiotic Resistance, Carbapenemase-Producing Enterobacteriaceae, Le Kremlin-Bicêtre, France

^fHigher Institute of Applied Sciences and Technology of Mahdia, University of Monastir, Monastir, Tunisia

^gFaculty of Pharmacy, University of Monastir, Monastir, Tunisia

^hFaculty of Medicine Ibn El Jassar, University of Sousse, Sousse, Tunisia

ABSTRACT The emergence of colistin-resistant *Klebsiella pneumoniae* (CoRKp) is a public health concern, since this antibiotic has become the last line of treatment for infections caused by multidrug-resistant (MDR) Gram negatives. In this study, we have investigated the molecular basis of colistin resistance in 13 MDR *K. pneumoniae* strains isolated from 12 patients in a teaching hospital in Sousse, Tunisia. Whole-genome sequencing (WGS) was used to decipher the molecular mechanism of colistin resistance and to identify the resistome of these CoRKp isolates. It revealed a genome of ca. 5.5 Mbp in size with a G+C content of 57%, corresponding to that commonly observed for *K. pneumoniae*. These isolates belonged to the 5 different sequence types (ST11, ST15, ST101, ST147, and ST392), and their resistome was composed of acquired β -lactamases, including extended-spectrum beta-lactamase and carbapenemase genes (*bla*_{CTX-M-15}, *bla*_{OXA-204r}, *bla*_{OXA-48r}, and *bla*_{NDM-1} genes), aminoglycoside resistance genes [*aac*(6')*Ib-cr*, *aph*(3'')*Ib*, *aph*(6)*I-d*, and *aac*(3)-*Ila*], and fosfomycin (*fosA*), fluoroquinolone (*qnr*-like), chloramphenicol, trimethoprim, and tetracycline resistance genes. All of the isolates were identified as having a mutated *mgrB* gene. Mapping reads with reference sequences of the most common genes involved in colistin resistance revealed several modifications in *mgrB*, *pmr*, and *pho* operons (deletions, insertions, and substitutions) likely affecting the function of these proteins. It is worth noting that among the 12 patients, 10 were treated with colistin before the isolation of CoRKp. No plasmid encoding *mcr-1* to *mcr-5* genes was found in these isolates. This study corresponds to the first molecular characterization of a collection of CoRKp strains in Tunisia and highlights that the small-transmembrane protein MgrB is a main mechanism for colistin resistance in *K. pneumoniae*.

KEYWORDS WGS, resistome, colistin resistance, BasR, BasS, MgrB, PhoP, PhoQ

Over the past 2 decades, carbapenemase-producing *Klebsiella pneumoniae* (CPKp) isolates have become a major global health concern, because they may cause severe infections with high mortality rates (1). The capacity of *K. pneumoniae* to accumulate enzymatic and nonenzymatic resistance mechanisms against most clinical

Received 2 August 2017 Returned for modification 22 August 2017 Accepted 27 November 2017

Accepted manuscript posted online 11 December 2017

Citation Jaidane N, Bonnin RA, Mansour W, Girlich D, Creton E, Cotellon G, Chaouch C, Boujaafar N, Bouallegue O, Naas T. 2018. Genomic insights into colistin-resistant *Klebsiella pneumoniae* from a Tunisian teaching hospital. Antimicrob Agents Chemother 62:e01601-17. <https://doi.org/10.1128/AAC.01601-17>.

Copyright © 2018 American Society for Microbiology. All Rights Reserved.

Address correspondence to Thierry Naas, Thierry.naas@aphp.fr.

cally available antibiotics, including beta-lactams, carbapenems, fluoroquinolones, and aminoglycosides, is increasing worldwide, leading the medical community to face limiting therapeutic options to deal with infections caused by this microorganism (2). While the volume from the pharmaceutical pipeline is waning, with a relative paucity of new antibiotics active against such strains, we are assisting in a resurgence in the use of colistin, an old class of cyclic polypeptide antibiotics that was discovered in 1947 (3). The target of the antimicrobial action of colistin is the negatively charged lipopolysaccharide (LPS) of the external membrane, allowing penetration through the outer membrane by displacing Ca^{2+} and Mg^{2+} . Products of *pmr* (polymyxin resistance) genes promote the covalent modification of lipopolysaccharide, reducing the attachment of colistin to the external surface of Gram-negative bacteria, and leads to bacterial cell death (4, 5). Nevertheless, reports of colistin-resistant *K. pneumoniae* (CoRKp) are increasing worldwide, likely as a result of selective pressure following exposure to colistin treatment (4, 6–8).

Colistin resistance mechanisms involve alteration of the lipid A biosynthetic pathway and modification of LPS surface (9, 10). These modifications reduce the electrostatic affinity between the cationic colistin and anionic LPS by modification with 4-amino-4-deoxy-L-arabinose (Ara4N) and phosphoethanolamine (PEtN) (10, 11). Modification of Ara4N is achieved by the *pmrHFIJKLM* operon and *pmrC* (10, 11). The most common molecular mechanisms sustaining this resistance showed that PmrAB, PmrD, PhoPQ, and the small transmembrane protein MgrB regulate expression of the *pmrHFIJKLM* operon (4, 7, 10–12). In addition, the *crrB* gene also has been described to be involved in colistin resistance in *K. pneumoniae* (9). Finally, the recent report of the plasmid-mediated colistin resistance *mcr-1*-like genes raised great medical concern worldwide (13). Since its initial description, the *mcr-1* gene has been identified worldwide in *Enterobacteriaceae* (mostly *Escherichia coli*) and recovered from human and animal samples (14).

While resistance to colistin has been reported worldwide, there is still a lack in many studies, especially from Tunisia (15), of an explanation of the exact mechanisms responsible for this resistance. Whole-genome sequencing of 13 CoRKp isolates was applied to gain insights into the molecular mechanisms sustaining colistin resistance, their resistomes, and their genetic relatedness.

(This work was presented in part at the 36th Interdisciplinary Meeting on Anti-Infectious Chemotherapy [RICAI], Paris, France, 2016.)

RESULTS AND DISCUSSION

Demographic, clinical, and microbiological data. During the 4-year study period, 2,826 *K. pneumoniae* isolates were recovered, of which 491 were carbapenem resistant (17.5%) and 13 were colistin resistant, as revealed by reduced inhibition zones around the colistin disks on routine antibiograms (0.4%). These 13 CoRKp isolates were isolated in urine samples of 12 patients admitted to different wards in a teaching hospital in Tunisia over a 4-year period (January 2012 to March 2016). These isolates exhibited a multidrug-resistant (MDR) profile (resistance to beta-lactams, including carbapenems for 7/13 isolates, and to aminoglycosides, to all of the tested fluoroquinolones, tetracycline, and trimethoprim-sulfamethoxazole) (Table 1).

The patients were of different ages (between 16 and 79 years old), presented different comorbidities, and were from different wards. Ten out of the 12 patients were previously treated with colistin, as this molecule is used in our hospital as the last-line therapeutic option for severe Gram-negative infection (Table 1). The majority of patients in the present study were admitted to intensive care units (ICUs), known to have chronic kidney disease, or under peritoneal dialysis. These patients (10/12) received colistin regimens adjusted to their renal function. Whether previous colistin exposure contributed to the development of colistin resistance was not addressed in this report. However, resistance to colistin due to selective pressure following prolonged exposure to colistin, especially with subinhibitory concentrations, has been reported (7, 16–18). On the other hand, colistin resistance may appear without any prior colistin exposure

TABLE 1 Demographic, clinical, and microbiological features for colistin-resistant *Klebsiella pneumoniae* isolates^a

Patient	Date of admission to hospital ^d (yr.mo)	Sample type	Ward	Treatment started prior to isolation of CoRkp	Isolate	Date of isolation (day.mo.yr)	MIC ^b (μg/ml)	ERT	DOR	MEM	IMP	TMO	TGC
1	C	Urine	Urology C	CST	C2	12.02.11	16	0.16	0.064	0.032	0.25	2.5	1
2	12.02	Urine	Nephrology	L VX + CIP + CST	C3	12.03.27	8	1	0.25	0.50	0.75	512	3
3	C	Urine	Urology C	CST	C4	12.03.22	32	0.032	0.032	0.023	0.094	3	1.5
4	C	Urine	Nephrology-peritoneal dialysis	NA	C5	13.12.12	16	0.50	0.25	0.25	0.38	192	2
5	13.11	Urine	Nephrology	IMP + FOF + OFX + CTX	C6	14.01.10	8	>32	24	>32	>32	>1024	1
		Urine			C7		8	>32	>32	>32	>32	>1024	0.75
6	15.02	Superficial Pus	Medical ICU	IMP + TG + CST	C8	15.03.10	>128	0.016	0.064	0.032	0.19	3	1
7	15.08	Urine	Urology	CTX + OFX + CST	C9	15.08.31	>128	6	3	4	1.5	128	3
8	15.09	Catheter	Surgical ICU	IMP + CTX + OFX + GEN + MTR + CST	C10	15.10.05	8	>32	6	12	4	>1024	0.75
9	15.10	Blood	Medical ICU	IMP + VNC + TEC + TZP + TIG + CST	C11	15.10.14	16	>32	5	12	4	>1024	1.5
10	15.11	Urine	Medical ICU	IMP + VNC + RIF + CIP + CST	C12	15.11.25	16	>32	6	8	4	>1024	1
11	15.10	Blood	Surgical ICU	IMP + VNC + RIF + AMC + AN + CST	C13	15.11.25	8	0.032	0.032	0.023	0.125	8	0.5
12	NA	Urine	Nephrology C	SXT + TIG + CST	C14	16.03.15	16	0.016	0.032	0.023	0.9	8	0.5

^aNA, not available; CST, colistin; DOR, doripenem; ERT, ertapenem; IMP, imipenem; MEM, meropenem; TGC, tigecycline; TMO, temocillin.

^bMIC was determined using Etest (bioMérieux-France) and interpreted according to updated EUCAST breakpoint tables for interpretation of MICs and zone diameters, 2015, version 5.0 (www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_5.0_Breakpoint_Table_01.pdf).

^cMICs for colistin were also determined by broth microdilution in cation-adjusted Mueller-Hinton broth (MHB-CA) according to CLSI guidelines.

^dC, consultation.

simply as the result of spontaneous mutations of genomic DNA or through horizontal gene transfer (19).

Resistome and genetic relatedness of CoR*Kp* isolates. The draft genome of the 13 CoR*Kp* isolates resulted in a mean of 3,671,577 reads, with an average length of 14,989 bp. The mean number of mapped contigs was 233, with an N_{50} of 150,349 bp. Genomic GC content showed little variation around an average value of 57%. The genomes ranged in size between 5,376,511 and 5,833,838 bp (with an average size of 5,591,208 bp), which is in accordance with the genome of *K. pneumoniae* (20).

Using Rast software, 5,285 coding sequences (CDSs) were identified in the genomes encoding several subsystems (591) involved in essential metabolism of the bacteria, including Gram-negative cell wall components (82 CDSs), RNA (61 CDSs), and DNA protein metabolism (256 CDSs and 142 CDSs, respectively). Accessory features were also present, such as those conferring resistance to antibiotics and toxic compounds, e.g., beta-lactams, fosfomycin, fluoroquinolones, arsenic, copper, mercury, etc.

In silico multilocus sequence typing (MLST) revealed 5 distinct sequence types (ST): ST01, ST147, ST11, ST15, and ST392 (Table 2).

A wide variety of antibiotic resistance genes against aminoglycoside, β -lactam, fluoroquinolone, macrolide, chloramphenicol, sulfonamide, fosfomycin, phenicol, tetracycline, co-trimoxazole, and rifampin antibiotics were found in the CoR*Kp* genomes (Table 2). Diverse drug resistance genes were found within the same ST type, highlighting the considerable genomic plasticity of clinical *K. pneumoniae* isolates. The resistome was in accordance with the antibiotic susceptibility testing results (Table 1). Indeed, all isolates harbored at least one beta-lactam resistance gene (*bla*_{CTX-M-15} or *bla*_{TEM-1B}), and seven isolates carried carbapenemases (*bla*_{OXA-48} [$n = 5$], *bla*_{OXA-204} [$n = 1$], and *bla*_{NDM-1} [$n = 1$]). *bla*_{OXA-48} was identified in clones ST101 and ST15, *bla*_{OXA-204} in ST147, and *bla*_{NDM} in ST11 (Table 2). The 13 isolates belonged to 5 STs. ST101, ST15, ST11, and ST147 have been described worldwide, as well as in Tunisia, and are associated with the carbapenemases OXA-48, KPC, OXA-204, and NDM and the extended-spectrum beta-lactamase (ESBL) CTX-M-15 (21–25). The single ST392 strain has never been described in Tunisia but was sporadically observed in three distinct countries related to KPC-2 in China (26), to NDM in Colombia (27), and to OXA-244 in Spain (28). In our study, ST-2 was associated with CTX-M-15 but not any carbapenemase.

All of the strains carried a fosfomycin resistance gene (*fosA*) and plasmid-mediated quinolone resistance (PMQR) genes: the bifunctional aminoglycoside resistance and fluoroquinolone-inactivating determinants *aac(6')Ib-cr* and *qnrB58*, present only in clone ST11 that harbored the *bla*_{NDM-1} gene.

Analysis of chromosomally encoded resistance genes revealed the presence of the quinolone efflux pumps *oqxAB*, the multidrug efflux pump, i.e., *acrB* and *mexCD*, and mutations in the quinolone resistance genes (gyrase and topoisomerases). Several mutations were found in the quinolone resistance-determining region (QRDR) of *gyrA*, leading to amino acid changes F83Y, A87N and F83I, and A87D in five isolates of ST101 and one of ST147 and of ST392, respectively. In addition, in all isolates, a single *gyrB* mutation leading to amino acid change V189A and several other amino acid changes were detected in *parC* and *parE*, likely being polymorphisms. Mutations in the QRDR, i.e., *gyrA*, *gyrB*, *parC*, and *parE*, are likely at the origin of the high level of fluoroquinolone resistance, but several PMQR genes [*qnrB* and *aac(6')Ib-cr*] and chromosomally located fluoroquinolone resistance genes have also been described (*oqxAB*, *acrB*, and *mexCD*).

Colistin resistance mechanisms. Plasmid-mediated colistin resistance genes *mcr-1* to *mcr-5* were not identified in the isolates of the present study (14). In order to uncover the molecular mechanisms sustaining the colistin resistance, we have targeted the role of alterations of the MgrB protein as well as those of the two-component regulatory systems (TCRS) *phoPQ* and *pmrAB*, *crrB*, a gene recently described to be responsible for the colistin resistant phenotype in *K. pneumoniae* (9), and the operon *arnBCADTEF*.

TABLE 2 Genomic features and epidemiological relatedness of the 13 *Klebsiella pneumoniae* isolates reported in the present study

Isolate ID	Yr of isolation	Isolate feature(s)					ST
		β -Lactamase	Carbapenemase	Fluoroquinolone	Other	Inc group(s)	
C6	2014	<i>bla</i> _{OXA-9} , <i>bla</i> _{SHV-11} , <i>bla</i> _{TEM-1A'} , <i>bla</i> _{OXA-1'} , <i>bla</i> _{CTX-M-15}	<i>bla</i> _{OXA-48}	<i>aac</i> (6') <i>lb-cr</i> , <i>oqxAB</i>	<i>aadA1</i> , <i>aac</i> (3)- <i>lla</i> , <i>aacA4</i> , <i>fosA</i> , <i>catB3</i> , <i>tet</i> (D), <i>dfrA14</i>	<i>IncFIB(K)</i> , <i>IncFIA(HI1)</i> , <i>IncL/M</i> (pOXA-48), <i>IncFII(K)</i> , <i>IncR</i>	101
C7	2014	<i>bla</i> _{OXA-1} , <i>bla</i> _{OXA-9} , <i>bla</i> _{SHV-1'} , <i>bla</i> _{TEM-1A'} , <i>bla</i> _{CTX-M-15}	<i>bla</i> _{OXA-48}	<i>aac</i> (6') <i>lb-cr</i> , <i>oqxAB</i>	<i>aadA1</i> , <i>aac</i> (3)- <i>lla</i> , <i>aac</i> (6')- <i>lb</i> , <i>fosA</i> , <i>catB3</i> , <i>tet</i> (D), <i>dfrA14</i>	<i>IncFIB(K)</i> , <i>IncFIA(HI1)</i> , <i>IncL/M</i> (pOXA-48), <i>IncFII(K)</i> , <i>IncR</i>	101
C10	2015	<i>bla</i> _{SHV-1'} , <i>bla</i> _{CTX-M-14b} , <i>bla</i> _{OXA-9'} , <i>bla</i> _{TEM-1A}	<i>bla</i> _{OXA-48}	<i>aac</i> (6') <i>lb-cr</i> , <i>oqxAB</i>	<i>aadA1</i> , <i>aph</i> (3')- <i>Vlb</i> , <i>aadA1</i> , <i>aac</i> (6')- <i>lb</i> , <i>aph</i> (3')- <i>lb</i> , <i>aac</i> (3)- <i>lla</i> , <i>fosA</i> , <i>mph</i> (A), <i>cmiA1</i> , <i>flaR</i> , <i>sul3</i> , <i>dfrA14</i>	<i>IncFIB(K)</i> , <i>IncFIA(HI1)</i> , <i>IncL/M</i> (pOXA-48), <i>IncFII(K)</i> , <i>IncR</i>	101
C11	2015	<i>bla</i> _{OXA-1} , <i>bla</i> _{OXA-9} , <i>bla</i> _{SHV-1'} , <i>bla</i> _{TEM-1A} , <i>bla</i> _{CTX-M-15}	<i>bla</i> _{OXA-48}	<i>aac</i> (6') <i>lb-cr</i> , <i>oqxAB</i>	<i>aadA1</i> , <i>aac</i> (6')- <i>lb-cr</i> , <i>aac</i> (3)- <i>lla</i> , <i>fosA</i> , <i>catB3</i> , <i>tet</i> (D), <i>dfrA14</i>	<i>IncFIB(K)</i> , <i>IncFIA(HI1)</i> , <i>IncL/M</i> (pOXA-48), <i>IncFII(K)</i> , <i>IncR</i>	101
C12	2015	<i>bla</i> _{SHV-1'} , <i>bla</i> _{CTX-M-15'} , <i>bla</i> _{OXA-1'} , <i>bla</i> _{OXA-9'} , <i>bla</i> _{TEM-1A}	<i>bla</i> _{OXA-48}	<i>aac</i> (6') <i>lb-cr</i> , <i>oqxAB</i>	<i>aadA1</i> , <i>aac</i> (3)- <i>lla</i> , <i>aacA4</i> , <i>fosA</i> , <i>catB3</i> , <i>tet</i> (D), <i>dfrA14</i>	<i>IncFIB(K)</i> , <i>IncFIA(HI1)</i> , <i>IncFII(K)</i> , <i>IncR</i>	101
C2	2012	<i>bla</i> _{SHV-2B'} , <i>bla</i> _{TEM-1B'} , <i>bla</i> _{CTX-M-15'} , <i>bla</i> _{OXA-1}	<i>bla</i> _{OXA-48}	<i>aac</i> (6') <i>lb-cr</i> , <i>oqxAB</i>	<i>aph</i> (6)- <i>ld</i> , <i>aac</i> (3)- <i>lla</i> , <i>aph</i> (3')- <i>lb</i> , <i>fosA</i> , <i>catB3</i> , <i>sul2</i> , <i>tet</i> (A), <i>dfrA14</i>	<i>IncFII</i> , <i>IncR</i> , <i>IncFIB(K)</i>	15
C3	2012	<i>bla</i> _{SHV-2B'} , <i>bla</i> _{OXA-1}	<i>bla</i> _{OXA-48}	<i>aac</i> (6') <i>lb-cr</i> , <i>oqxAB</i>	<i>aac</i> (3)- <i>lla</i> , <i>aadA1</i> , <i>fosA</i> , <i>mph</i> (A), <i>catB3</i> , <i>sul1</i> , <i>tet</i> (A), <i>dfrA15</i>	<i>IncH11B</i> , <i>IncR</i> , <i>IncL/M</i> (pOXA-48)	15
C4	2013	<i>bla</i> _{SHV-2B'} , <i>bla</i> _{CTX-M-15'} , <i>bla</i> _{TEM-1B'} , <i>bla</i> _{OXA-1}	<i>bla</i> _{OXA-48}	<i>aac</i> (6') <i>lb-cr</i> , <i>oqxAB</i>	<i>aph</i> (6)- <i>ld</i> , <i>aph</i> (3')- <i>lb</i> , <i>aac</i> (3)- <i>lla</i> , <i>fosA</i> , <i>catB3</i> , <i>sul2</i> , <i>dfrA14</i>	<i>IncL/M</i> (pMU407)	15
C8	2015	<i>bla</i> _{SHV-2B'} , <i>bla</i> _{CTX-M-15'} , <i>bla</i> _{TEM-1B'} , <i>bla</i> _{OXA-1}	<i>bla</i> _{OXA-48}	<i>aac</i> (6') <i>lb-cr</i> , <i>oqxAB</i>	<i>aph</i> (3')- <i>lb</i> , <i>aph</i> (6)- <i>ld</i> , <i>aac</i> (3)- <i>lla</i> , <i>fosA</i> , <i>catB3</i> , <i>sul2</i> , <i>tet</i> (A), <i>dfrA14</i>	<i>IncFII</i> , <i>IncFIB(K)</i> , <i>IncR</i>	15
C9	2015	<i>bla</i> _{SHV-11'} , <i>bla</i> _{OXA-1'} , <i>bla</i> _{CTX-M-15'} , <i>bla</i> _{OXA-10}	<i>bla</i> _{NDM-1}	<i>aac</i> (6') <i>lb-cr</i> , <i>oqxAB</i> , <i>qnrB58</i>	<i>aadA1</i> , <i>aac</i> (6')- <i>lb</i> , <i>fosA</i> , <i>mph</i> (A), <i>catA2</i> , <i>catB3</i> , <i>ARR-3</i> , <i>sul1</i> , <i>tet</i> (A)	<i>IncFII(K)</i> , <i>IncN</i> , <i>IncFIB(K)</i> , <i>IncR</i> , <i>IncFIA(HI1)</i>	11
C14	2016	<i>bla</i> _{SHV-11'} , <i>bla</i> _{CTX-M-15}	<i>bla</i> _{OXA-204}	<i>aac</i> (6') <i>lb-cr</i> , <i>oqxAB</i>	<i>fosA</i> , <i>mph</i> (A), <i>ARR-3</i> , <i>sul1</i> , <i>tet</i> (A)	<i>IncFII(K)</i> , <i>IncFIB(K)</i> , <i>IncR</i> , <i>IncN</i>	11
C5	2013	<i>bla</i> _{TEM-1B'} , <i>bla</i> _{SHV-11'} , <i>bla</i> _{CTX-M-15}	<i>bla</i> _{OXA-204}	<i>aac</i> (6') <i>lb-cr</i> , <i>oqxAB</i>	<i>aph</i> (3')- <i>lb</i> , <i>aacA4</i> , <i>aph</i> (6)- <i>ld</i> , <i>aph</i> (3')- <i>lc</i> , <i>fosA</i> , <i>ere</i> (B), <i>ere</i> (A), <i>catB3</i> , <i>catA1</i> , <i>flaR</i> , <i>ARR-2</i> , <i>sul2</i> , <i>sul1</i> , <i>tet</i> (A), <i>dfrA5</i>	<i>IncA/C2</i> , <i>IncFII(K)</i> , <i>IncFIA(HI1)</i> , <i>IncH11B</i>	147
C13	2015	<i>bla</i> _{SHV-11'} , <i>bla</i> _{CTX-M-15'} , <i>bla</i> _{TEM-1B'} , <i>bla</i> _{OXA-1}	<i>bla</i> _{OXA-48}	<i>aac</i> (6') <i>lb-cr</i> , <i>oqxAB</i>	<i>aph</i> (3')- <i>lb</i> , <i>aph</i> (6)- <i>ld</i> , <i>aac</i> (3)- <i>lla</i> , <i>fosA</i> , <i>catB3</i> , <i>sul2</i> , <i>dfrA14</i>	<i>IncFII(K)</i> , <i>IncFIB(K)</i>	392




FIG 1 DNA and deduced protein sequence alignments of *mgrB* alleles. (A) DNA sequence alignments for wild-type *mgrB* gene from colistin-susceptible *K. pneumoniae* strain NH53 (accession number [KF852760](https://ncbi.nlm.nih.gov/nucl/KF852760)) (8) and *mgrB* genes from the present study. The insertion of an A in C13 is boldfaced and underlined. The substitutions (T83G) are boldfaced. The dashes indicate deletions of 20 to 26 amino acids or a complete deletion in isolate C10. (B) Alignment of wild-type MgrB from colistin-susceptible *K. pneumoniae* strain NH53 (accession number [KF852760](https://ncbi.nlm.nih.gov/nucl/KF852760)) (8) and MgrB from the isolates of the present study. Changes in amino acid sequences compared to the WT MgrB protein sequence are indicated in boldface, and additional amino acids compared to the sequence of WT MgrB protein are indicated in gray. MgrB protein of the C13 isolate corresponds to a short nonfunctional protein due to the frameshift mutation in its corresponding gene. MgrB proteins of C4, C8, C3, C7, C6, and C2 corresponded of nonfunctional proteins (truncated or longer) due to insertional inactivation by diverse IS within their corresponding *mgrB* gene. For isolate C10, the complete *mgrB* allele was deleted (indicated by dashes).

Sequence analysis revealed that all of the *mgrB* genes were mutated, resulting in amino acid sequence changes of the small regulatory transmembrane protein MgrB (Fig. 1A and B and Table 3): (i) missense and frameshift mutations resulting in amino acid changes or premature ending of the protein, respectively; (ii) complete deletions

TABLE 3 Mutations reported in the present study within genes involved in colistin resistance (*mgrB*, *pmrAB*, *phoPQ*, *eptA*)

Isolate	Mutation annotation ^a		EptA														ST
	<i>mgrB</i> ^b	<i>pmrA</i> ^c	<i>pmrB</i> ^c	<i>phoP</i> ^c	<i>phoQ</i> ^c	S25	F27	L50	P135	V138	A148	S204	L257	R319	E354	G469	
C6	F28C; IS1 insertion	A217V	T246A	#	ΔK2-L6	G				I	T	F		Q	K	V	101
C7	F28C; IS1 insertion	A217V	T246A	#	ΔK2-L6	G				I	T	F		Q	K	V	101
C11	F28C	A217V	T246A	#	ΔK2-L6	G				I	T	F		Q	K	V	101
C12	F28C	A217V	T246A	#	ΔK2-L6	G				I	T	F		Q	K	V	101
C10	Complete Δ	A217V	T246A	#	ΔK2-L6	G				I	T	F		Q	K	V	101
C2	ΔK2-V7; ΔT41	#	#	#	#					I	T	F	S		K	V	15
C3	F28C; ΔT40	#	#	#	#					I	T	F	S		K	V	15
C4	F28C; ΔI41	#	#	#	#					I	T	F	S		K	V	15
C8	F28C; ΔI40	#	#	#	#					I	T	F	S		K	V	15
C9	F28C	#	T246A; R256G	#	ΔK2-L6	G				I	T	F		Q	K	V	11
C14	F28C	#	T157P; T246A; R256G	#	ΔK2-L6		C			I	T	F		Q	K	V	11
C13	Δ24N	#	T246A; R256G	#	ΔK2-L6		C	V	A	I	T	F			K	V	392
C5	F28C	#	T246A; R256G	#	ΔK2-L6		C	V	A	I	T	F			K	V	147

^a#, identical to the wild-type strain; Δ, deletion.

^bAligned with *Klebsiella pneumoniae* strain NH53 MgrB (GenBank accession no. [KF852760.1](#)) (8).

^cAligned with *Klebsiella pneumoniae* subsp. *pneumoniae* MGH 78578 *pmrAB* and *phoPQ* (GenBank accession no. [CP000647](#)) (16).

of the *mgrB* gene in isolate C10; (iii) and insertional inactivation caused by insertion sequences (IS) belonging to several IS families (IS1382-like, IS5-like, and IS1-like families). Due to these insertions, the length and the sequence of the resulting MgrB protein was either reduced (40, 42, and 43 amino acids [aa]) or increased (72 aa) compared to that of the wild-type (WT) MgrB protein (47 aa). For C13, and due to the frameshift, the resulting MgrB protein is only 24 aa long, with only 3 aa corresponding to the wild-type sequence. The T83G amino acid substitution was identified in all MgrB proteins derived from all five unrelated ST types.

Our results showed that colistin resistance in *K. pneumoniae* was directly linked to mutations identified within the *mgrB* gene, as previously suggested (29), and that insertional inactivation mediated by mobile DNA, even though described in the literature as the most prevalent mechanism involved in colistin resistance in *K. pneumoniae* (5, 8, 29–32), is not the only mechanism leading to MgrB inactivation. Indeed, complementation with a WT *mgrB* allele of T83G-MgrB strains (C6, C11, and C14) resulted in restoration of colistin susceptibility, suggesting that the observed mutations are at the origin of colistin resistance (Table 4).

In order to see whether the inserted ISs were already present in the chromosome of the different *K. pneumoniae* isolates, blast searches were performed against the entire contigs. Several copies of IS5-like elements were present in all isolates, while IS1382-like and IS1-like were present only in the respective isolates where they have been found, suggesting an insertion from a plasmid.

Sequence analysis of *pmrA*, *pmrB*, *phoP*, *phoQ*, operon *arnBCADTEF*, and *eptA* (*pmrC*) genes known to be involved in LPS synthesis revealed several polymorphisms in nucleotide sequences compared to the wild-type sequence of *Klebsiella pneumoniae* subsp. *pneumoniae* MGH 78578 (GenBank accession no. [CP000647](#)) (Table 3). These polymorphisms were linked to the different ST types. Within strains belonging to ST15, no variation compared to wild-type protein sequences was detected for *pmrAB* or

TABLE 4 Complementation assays

Isolate	MgrB mutation	Colistin MICs (μg/ml)
C6	F28C; IS1 insertion	8
C6 + pMgrB		0.5
C11	F28C	16
C11 + pMgrB		2
C14	F28C	16
C14 + pMgrB		1

phoPQ, but 6 amino acid changes were observed in all EptA proteins (V138I, A148T, S204F, L257S, E354K, and G469V). The *rrbB* gene was identical to that of the WT sequence of *K. pneumoniae* (9).

PmrA variant A217V, PmrB variant T246A, and PhoPQ variant Δ K2-L6 were found in all isolates belonging to ST101 and did not correspond to any mutations previously identified as contributing to colistin resistance.

For strains of ST11, ST147, and ST392, PmrA and PhoP were identical to the wild-type proteins of *K. pneumoniae* subsp. *pneumoniae* MGH 78578 (GenBank accession no. CP000647), while a novel PmrB variant (T246A, R256G) and PhoQ (Δ K2-L6) were detected. Finally, a PmrB variant, T157P, initially described by Jayol et al. (33) as contributing to colistin resistance, has been described in isolate C14. Whether these changes influence colistin resistance is not known, as some have never been described and likely correspond to polymorphisms. In order to study the real contribution of these novel variants in colistin resistance, further experiments are necessary, such as complementation assays with wild-type alleles and transcriptional studies.

Plasmids and conjugation. All of the *K. pneumoniae* isolates possessed several plasmids varying in size, as revealed by Kleser plasmid analysis (34) (see Fig. S2 in the supplemental material). Most of the β -lactam resistance-carrying plasmids could be transferred by conjugation (data not shown) (35), but no colistin resistance determinant could be transferred. PCR experiments confirmed the presence of the *bla*_{CTX-M}, *bla*_{OXA-48}-like, and *bla*_{NDM} genes in the transconjugants, but we were not able to reconstruct these plasmids using our Illumina-generated sequencing data. Nevertheless, using *in silico* analysis, the presence of several Inc groups, namely, FII, FII(K), FIB(K), FIA(HI1), HI1B, L/M, A/C2, N, and R types (36), were found in the *K. pneumoniae* isolates (Table 2). Some of these Inc groups have been clearly incriminated in horizontal gene transfer of plasmids encoding antibiotic resistance determinants, such as IncL/M and the *bla*_{OXA-48} gene, Inc FII and *bla*_{CTX-M-15}, and IncR and *bla*_{NDM} (37, 38).

Conclusions. This work corresponds, to the best of our knowledge, to the first genomic investigation of colistin resistance in *K. pneumoniae* from a clinical setting from Tunisia, and it showed emergence of colistin resistance as early as 2012, with a subsequent polyclonal dissemination. Here, we were able to determine the major role of MgrB in colistin resistance in *K. pneumoniae*. The genomic data of our study may serve for future comparative genomic and molecular epidemiological studies aiming at deciphering the genomic basis of the emergence of resistance mechanisms and the dynamics of the spread of MDR *K. pneumoniae* strains.

MATERIALS AND METHODS

Bacterial strains and clinical data. The Sahloul university hospital is a 629-bed teaching hospital with specialty services, including an operating room and five intensive care units. CoRkp strains were from the Sahloul university teaching hospital (629 beds) and were identified through review of the clinical microbiology laboratory database from January 2012 to March 2016. The clinical data were retrieved from the medical records of each patient, and the data on colistin use during the hospitalization were obtained from pharmacy records.

Identification and antimicrobial susceptibility testing. Thirteen CoRkp clinical isolates were retained from 12 patients and included in this study. Isolates were identified by matrix-assisted laser desorption ionization–time of flight mass spectrometry (MALDI-TOF MS) as previously described (39). Routine antibiograms were determined by disk diffusion on Mueller-Hinton agar plates at 37°C. The MICs of β -lactams, including ertapenem, imipenem, meropenem, and doripenem, in addition to tigecycline, were determined by Etest (bioMérieux-France).

For strains showing resistance to colistin (CR), MICs were determined by broth microdilution (BMD) in cation-adjusted Mueller-Hinton broth (MHB-CA) and interpreted according to updated CLSI guidelines (<http://www.captodayonline.com/new-clsi-editions-m100-s24-em100/>). Colistin sulfate (obtained from Sigma-Aldrich [St. Louis, MO]) was tested with Tween 80 (with a final concentration of 0.002%) over a range of dilutions from 0.125 to 128 μ g/ml. All results were interpreted according to updated EUCAST breakpoint tables for interpretation of MICs and zone diameters of 2015, version 5.0 (www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_5.0_Breakpoint_Table_01.pdf).

Plasmid identification and transformation. Plasmid DNA of all carbapenem-resistant *K. pneumoniae* (CR-KP) isolates was extracted using the Kleser method as previously described (34). Plasmids of ca. 154, 66, 48, and 7 kb of *Escherichia coli* NCTC 50192 were used as plasmid size markers. Plasmid DNA was analyzed by agarose gel electrophoresis.

Detection of carbapenemase activity and β -lactamase genes. The carbapenemase activity was searched for using the Carba NP test as previously described (30). Class A ESBLs and carbapenem-hydrolyzing resistance genes were sought by PCR as previously described (35).

Whole-genome sequencing. The genomic DNA was extracted from overnight cultures in LB agar (Bio-Rad, Marnes-la-Coquette, France) using an UltraClean microbial DNA isolation kit (Mo Bio Laboratories). Genomic DNA quantification was performed using a Qubit fluorometer (Life Technologies, Carlsbad, CA) and adjusted to 0.2 ng/ μ l. Library preparation was performed using a Nextera XT DNA sample preparation kit (Illumina, San Diego, CA) and Illumina MiSeq 2000 sequencer with v3 chemistry using 2- by 150-bp paired-end reads for sequencing. The 150-bp paired-end reads were *de novo* assembled using CLC Genomic Workbench with a minimum contig length of 200 bp.

Antibiotic resistance-related genes were predicted using the ResFinder database, version 2.1 (40), with the following parameters: "all databases" was used for antimicrobial configuration, type of reads was "assembled genomes/contigs," and we used thresholds of 98% identity and 80% coverage between sequences. This data set of resistance genes was complemented with BLASTp searches against the ARDB (Antibiotic Resistance Genes Database), version 1.1 (41), the using "resistance gene complete" database with 40% identity and E value of 0.0001. Multilocus sequence typing (MLST) was performed *in silico* according to the *K. pneumoniae* MLST database (<http://bigsdbs.pasteur.fr/klebsiella/klebsiella.html>). For the detection and typing of the presence of known replicon types of plasmids in the isolates studied, Plasmid Finder and pMLST (<http://cge.cbs.dtu.dk/services/PlasmidFinder/>) were used (40).

MgrB complementation assay. The wild-type *mgrB* allele was cloned from *K. pneumoniae* subsp. *pneumoniae* MGH 78578 (GenBank accession no. CP000647) into cloning vector pCRscriptCm in the same orientation as the plasmid-borne promoter pLAC. The resulting plasmid was named pMgrB. Three representative isolates (C6, C11, and C14) were prepared to be electrocompetent, as previously described (35), and subsequently pMgrB was electroporated into them (35). Electroporants were selected on 100 μ g/ml chloramphenicol containing trypticase soy agar plates.

Accession number(s). The whole-genome shotgun project has been deposited at DDBJ/ENA/GenBank under the accession numbers MSYN00000000 to MSZF00000000.

ACKNOWLEDGMENTS

We thank the many dedicated staff members who helped with data collection and technical issues: the members of the French National Reference Center for Antibiotic Resistance, Carbapenemase-Producing Enterobacteriaceae, and the staff of the Laboratory of Clinical Microbiology, University Hospital of Sahloul, Sousse, Tunisia. We thank in particular Kalboussi Nesrine (Pharmacy Department of University Hospital of Sahloul, Sousse, Tunisia).

This work was funded by a grant from the Ministère de l'Éducation Nationale et de la Recherche (EA7361), Université Paris Sud. R.A.B. and T.N. are members of the Laboratory of Excellence LERMIT, supported by a grant from ANR (ANR-10-LABX-33). In addition, this study was partially supported by the University Hospital of Sahloul, Sousse, Tunisia.

We have no conflicts of interest to declare.

REFERENCES

- Munoz-Price LS, Poirel L, Bonomo RA, Schwaber MJ, Daikos GL, Cormican M, Cornaglia G, Garau J, Gniadkowski M, Hayden MK, Kumarasamy K, Livermore DM, Maya JJ, Nordmann P, Patel JB, Paterson DL, Pitout J, Villegas MV, Wang H, Woodford N, Quinn JP. 2013. Clinical epidemiology of the global expansion of *Klebsiella pneumoniae* carbapenemases. *Lancet Infect Dis* 13:785–796. [https://doi.org/10.1016/S1473-3099\(13\)70190-7](https://doi.org/10.1016/S1473-3099(13)70190-7).
- Lee C-R, Lee JH, Park KS, Kim YB, Jeong BC, Lee SH. 2016. Global dissemination of carbapenemase-producing *Klebsiella pneumoniae*: epidemiology, genetic context, treatment options, and detection methods. *Front Microbiol* 7:895. <https://doi.org/10.3389/fmicb.2016.00895>.
- Falagas ME, Michalopoulos A. 2006. Polymyxins: old antibiotics are back. *Lancet* 367:633–634. [https://doi.org/10.1016/S0140-6736\(06\)68241-X](https://doi.org/10.1016/S0140-6736(06)68241-X).
- Cannatelli A, D'Andrea MM, Giani T, Di Pilato V, Arena F, Ambretti S, Gaibani P, Rossolini GM. 2013. In vivo emergence of colistin resistance in *Klebsiella pneumoniae* producing KPC-type carbapenemases mediated by insertional inactivation of the PhoQ/PhoP *mgrB* regulator. *Antimicrob Agents Chemother* 57:5521–5526. <https://doi.org/10.1128/AAC.01480-13>.
- Cannatelli A, Giani T, D'Andrea MM, Di Pilato V, Arena F, Conte V, Tryfinopoulou K, Vatopoulos A, Rossolini GM, COLGRIT Study Group. 2014. *MgrB* inactivation is a common mechanism of colistin resistance in KPC-producing *Klebsiella pneumoniae* of clinical origin. *Antimicrob Agents Chemother* 58:5696–5703. <https://doi.org/10.1128/AAC.03110-14>.
- Lopez-Rojas R, McConnell MJ, Jimenez-Mejias ME, Dominguez-Herrera J, Fernandez-Cuenca F, Pachon J. 2013. Colistin resistance in a clinical *Acinetobacter baumannii* strain appearing after colistin treatment: effect on virulence and bacterial fitness. *Antimicrob Agents Chemother* 57:4587–4589. <https://doi.org/10.1128/AAC.00543-13>.
- Cannatelli A, Di Pilato V, Giani T, Arena F, Ambretti S, Gaibani P, D'Andrea MM, Rossolini GM. 2014. In vivo evolution to colistin resistance by *PmrB* sensor kinase mutation in KPC-producing *Klebsiella pneumoniae* is associated with low-dosage colistin treatment. *Antimicrob Agents Chemother* 58:4399–4403. <https://doi.org/10.1128/AAC.02555-14>.
- Olaitan AO, Diene SM, Kempf M, Berrazeg M, Bakour S, Gupta SK, Thongmalayvong B, Akkhavong K, Somphavong S, Paboriboune P, Chaisiri K, Komalamisra C, Adelowo OO, Fagade OE, Banjo OA, Oke AJ, Adler A, Assouf MV, Morand S, Raoult D, Rolain J-M. 2014. Worldwide emergence of colistin resistance in *Klebsiella pneumoniae* from healthy humans and patients in Lao PDR, Thailand, Israel, Nigeria and France owing to inactivation of the PhoP/PhoQ regulator *mgrB*: an epidemiological and molecular study. *Int J Antimicrob Agents* 44:500–507. <https://doi.org/10.1016/j.ijantimicag.2014.07.020>.
- Wright MS, Suzuki Y, Jones MB, Marshall SH, Rudin SD, van Duin D, Kaye K, Jacobs MR, Bonomo RA, Adams MD. 2015. Genomic and transcriptomic analyses of colistin-resistant clinical isolates of *Klebsiella pneumoniae* reveal multiple pathways of resistance. *Antimicrob Agents Chemother* 59:536–543. <https://doi.org/10.1128/AAC.04037-14>.
- Olaitan AO, Morand S, Rolain J-M. 2014. Mechanisms of polymyxin

- resistance: acquired and intrinsic resistance in bacteria. *Front Microbiol* 5:643. <https://doi.org/10.3389/fmicb.2014.00643>.
11. Cheng H-Y, Chen Y-F, Peng H-L. 2010. Molecular characterization of the PhoPQ-PmrD-PmrAB mediated pathway regulating polymyxin B resistance in *Klebsiella pneumoniae* CG43. *J Biomed Sci* 17:60. <https://doi.org/10.1186/1423-0127-17-60>.
 12. Chen HD, Groisman EA. 2013. The biology of the PmrA/PmrB two-component system: the major regulator of lipopolysaccharide modifications. *Annu Rev Microbiol* 67:83–112. <https://doi.org/10.1146/annurev-micro-092412-155751>.
 13. Liu YY, Wang Y, Walsh TR, Yi LX, Zhang R, Spencer J, Doi Y, Tian G, Dong B, Huang X, Yu LF, Gu D, Ren H, Chen X, Lv L, He D, Zhou H, Liang Z, Liu JH, Shen J. 2016. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. *Lancet Infect Dis* 16(2):161–168. [https://doi.org/10.1016/S1473-3099\(15\)00424-7](https://doi.org/10.1016/S1473-3099(15)00424-7).
 14. Jeannot K, Bolard A, Plesiat P. 2017. Resistance to polymyxins in Gram-negative organisms. *Int J Antimicrob Agents* 49(5):526–535. <https://doi.org/10.1016/j.ijantimicag.2016.11.029>.
 15. Mezghani Maalej S, Rekiq Meziou M, Mahjoubi F, Hammami A. 2012. Epidemiological study of Enterobacteriaceae resistance to colistin in Sfax (Tunisia). *Médecine Mal Infect* 42:256–263.
 16. Kempf I, Fleury MA, Drider D, Bruneau M, Sanders P, Chauvin C, Madec J-Y, Jouy E. 2013. What do we know about resistance to colistin in Enterobacteriaceae in avian and pig production in Europe? *Int J Antimicrob Agents* 42:379–383. <https://doi.org/10.1016/j.ijantimicag.2013.06.012>.
 17. Halaby T, al Naiemi N, Kluytmans J, van der Palen J, Vandenbroucke-Grauls CMJE. 2013. Emergence of colistin resistance in Enterobacteriaceae after the introduction of selective digestive tract decontamination in an intensive care unit. *Antimicrob Agents Chemother* 57:3224–3229. <https://doi.org/10.1128/AAC.02634-12>.
 18. Lee J-Y, Choi M-J, Choi HJ, Ko KS. 2015. Preservation of acquired colistin resistance in gram-negative bacteria. *Antimicrob Agents Chemother* 60:609–612. <https://doi.org/10.1128/AAC.01574-15>.
 19. Olaitan AO, Morand S, Rolain J-M. 2016. Emergence of colistin-resistant bacteria in humans without colistin usage: a new worry and cause for vigilance. *Int J Antimicrob Agents* 47:1–3. <https://doi.org/10.1016/j.ijantimicag.2015.11.009>.
 20. Liu P, Li P, Jiang X, Bi D, Xie Y, Tai C, Deng Z, Rajakumar K, Ou H-Y. 2012. Complete genome sequence of *Klebsiella pneumoniae* subsp. *pneumoniae* HS11286, a multidrug-resistant strain isolated from human sputum. *J Bacteriol* 194:1841–1842. <https://doi.org/10.1128/JB.00043-12>.
 21. Ben Tanfous F, Alonso CA, Achour W, Ruiz-Ripa L, Torres C, Ben Hassen A. 2016. First description of KPC-2-producing *Escherichia coli* and ST15 OXA-48-positive *Klebsiella pneumoniae* in Tunisia. *Microb Drug Resist* 23:365–375.
 22. Grami R, Mansour W, Ben Haj Khalifa A, Dahmen S, Chatre P, Haenni M, Aouni M, Madec J-Y. 2016. Emergence of ST147 *Klebsiella pneumoniae* producing OXA-204 carbapenemase in a university hospital, Tunisia. *Microb Drug Resist* 22:137–140. <https://doi.org/10.1089/mdr.2014.0278>.
 23. Charfi K, Mansour W, Ben Haj Khalifa A, Mastouri M, Aouni M, Mammeri H. 2015. Emergence of OXA-204 β -lactamase in Tunisia. *Diagn Microbiol Infect Dis* 82:314–317. <https://doi.org/10.1016/j.diagmicrobio.2015.04.003>.
 24. Mansour W, Grami R, Ben Haj Khalifa A, Dahmen S, Châtre P, Haenni M, Aouni M, Madec J-Y. 2015. Dissemination of multidrug-resistant blaCTX-M-15/IncFIIk plasmids in *Klebsiella pneumoniae* isolates from hospital- and community-acquired human infections in Tunisia. *Diagn Microbiol Infect Dis* 83:298–304. <https://doi.org/10.1016/j.diagmicrobio.2015.07.023>.
 25. Messaoudi A, Haenni M, Mansour W, Saras E, Bel Haj Khalifa A, Chaouch C, Najja W, Boujâafar N, Bouallège O, Madec J-Y. 2017. ST147 NDM-1-producing *Klebsiella pneumoniae* spread in two Tunisian hospitals. *J Antimicrob Chemother* 72:315–316. <https://doi.org/10.1093/jac/dkw401>.
 26. Yang J, Ye L, Guo L, Zhao Q, Chen R, Luo Y, Chen Y, Tian S, Zhao J, Shen D, Han L. 2013. A nosocomial outbreak of KPC-2-producing *Klebsiella pneumoniae* in a Chinese hospital: dissemination of ST11 and emergence of ST37, ST392 and ST395. *Clin Microbiol Infect* 19:E509–E515. <https://doi.org/10.1111/1469-0691.12275>.
 27. Rojas LJ, Wright MS, De La Cadena E, Mota G, Hujer KM, Villegas MV, Adams MD, Bonomo RA. 2016. Initial assessment of the molecular epidemiology of bla NDM-1 in Colombia. *Antimicrob Agents Chemother* 60:4346–4350. <https://doi.org/10.1128/AAC.03072-15>.
 28. Oteo J, Hernandez JM, Espasa M, Fleites A, Saez D, Bautista V, Perez-Vazquez M, Fernandez-Garcia MD, Delgado-Iribarren A, Sanchez-Romero I, Garcia-Picazo L, Miguel MD, Solis S, Aznar E, Trujillo G, Mediavilla C, Fontanals D, Rojo S, Vindel A, Campos J. 2013. Emergence of OXA-48-producing *Klebsiella pneumoniae* and the novel carbapenemases OXA-244 and OXA-245 in Spain. *J Antimicrob Chemother* 68:317–321. <https://doi.org/10.1093/jac/dks383>.
 29. Poirel L, Jayol A, Bontron S, Villegas M-V, Ozdamar M, Türkoglu S, Nordmann P. 2015. The mgrB gene as a key target for acquired resistance to colistin in *Klebsiella pneumoniae*. *J Antimicrob Chemother* 70:75–80. <https://doi.org/10.1093/jac/dku323>.
 30. Nordmann P, Poirel L, Dortet L. 2012. Rapid detection of carbapenemase-producing Enterobacteriaceae. *Emerg Infect Dis* 18:1503–1507. <https://doi.org/10.3201/eid1809.120355>.
 31. Cheng Y-H, Lin T-L, Pan Y-J, Wang Y-P, Lin Y-T, Wang J-T. 2015. Colistin resistance mechanisms in *Klebsiella pneumoniae* strains from Taiwan. *Antimicrob Agents Chemother* 59:2909–2913. <https://doi.org/10.1128/AAC.04763-14>.
 32. Lopez-Camacho E, Gomez-Gil R, Tobes R, Manrique M, Lorenzo M, Galvan B, Salvarelli E, Moatassim Y, Salanueva IJ, Pareja E, Codoner FM, Alvarez-Tejado M, Garcillan-Barcia MP, De la Cruz F, Mingorance J. 2014. Genomic analysis of the emergence and evolution of multidrug resistance during a *Klebsiella pneumoniae* outbreak including carbapenem and colistin resistance. *J Antimicrob Chemother* 69:632–636. <https://doi.org/10.1093/jac/dkt419>.
 33. Jayol A, Poirel L, Brink A, Villegas M-V, Yilmaz M, Nordmann P. 2014. Resistance to colistin associated with a single amino acid change in protein PmrB among *Klebsiella pneumoniae* isolates of worldwide origin. *Antimicrob Agents Chemother* 58:4762–4766. <https://doi.org/10.1128/AAC.00084-14>.
 34. Kieser T. 1984. Factors affecting the isolation of CCC DNA from Streptomyces lividans and *Escherichia coli*. *Plasmid* 12:19–36. [https://doi.org/10.1016/0147-619X\(84\)90063-5](https://doi.org/10.1016/0147-619X(84)90063-5).
 35. Cuzon G, Ouanich J, Gondret R, Naas T, Nordmann P. 2011. Outbreak of OXA-48-positive carbapenem-resistant *Klebsiella pneumoniae* isolates in France. *Antimicrob Agents Chemother* 55:2420–2423. <https://doi.org/10.1128/AAC.01452-10>.
 36. Carattoli A, Zankari E, Garcia-Fernandez A, Voldby Larsen M, Lund O, Villa L, Moller Aarestrup F, Hasman H. 2014. In silico detection and typing of plasmids using PlasmidFinder and plasmid multilocus sequence typing. *Antimicrob Agents Chemother* 58:3895–3903. <https://doi.org/10.1128/AAC.02412-14>.
 37. Garcia-Fernandez A, Fortini D, Veldman K, Mevius D, Carattoli A. 2009. Characterization of plasmids harbouring qnrS1, qnrB2 and qnrB19 genes in *Salmonella*. *J Antimicrob Chemother* 63:274–281. <https://doi.org/10.1093/jac/dkn470>.
 38. Carattoli A, Bertini A, Villa L, Falbo V, Hopkins KL, Threlfall EJ. 2005. Identification of plasmids by PCR-based replicon typing. *J Microbiol Methods* 63:219–228. <https://doi.org/10.1016/j.mimet.2005.03.018>.
 39. Seng P, Drancourt M, Gouriet F, La Scola B, Fournier P-E, Rolain JM, Raoult D. 2009. Ongoing revolution in bacteriology: routine identification of bacteria by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. *Clin Infect Dis Off Publ Infect Dis Soc Am* 49:543–551. <https://doi.org/10.1086/600885>.
 40. Zankari E, Hasman H, Cosentino S, Vestergaard M, Rasmussen S, Lund O, Aarestrup FM, Larsen MV. 2012. Identification of acquired antimicrobial resistance genes. *J Antimicrob Chemother* 67:2640–2644. <https://doi.org/10.1093/jac/dks261>.
 41. Liu B, Pop M. 2009. ARDB—Antibiotic Resistance Genes Database. *Nucleic Acids Res* 37:D443–D447. <https://doi.org/10.1093/nar/gkn656>.